Abstract
Background In the Philippines, stroke is the second most common cause of mortality and is among the five leading causes of disability. Mannitol, a hyperosmolar agent, is a mainstay for the treatment of brain edema caused by elevated intracranial pressure in acute stroke patients. It is a potent diuretic that may trigger intravascular volume depletion, electrolyte imbalance, and renal tubular damage, which may lead to acute kidney injury in acute stroke.
Objective This study aims to describe the incidence, identify the risk factors, and determine the clinical outcomes of mannitol-induced acute kidney injury among acute stroke patients admitted to East Avenue Medical Center from January 1, 2019, to December 31, 2021.
Methods This is a retrospective study conducted at the East Avenue Medical Center, a tertiary training hospital in Quezon City, Philippines. A three-year chart review of acute stroke patients who developed mannitol-induced acute kidney injury (MI-AKI) was conducted.
Result A total of 348 eligible acute stroke patients were included in the study. Of these, 60 patients (17%) developed MI-AKI during confinement. There was a higher predominance among males than females with more than half of patients (65%) belonging to the 40 to 59 years age group. The risk factors identified were high National Institutes of Health Stroke Scale (NIHSS) score, chronic kidney disease, possibly cardiovascular disease, such as heart failure, intraparenchymal type hemorrhagic stroke, and high mannitol infusion dose >0.40g/kg in more than 48 hours. A high mortality rate was observed among MI-AKI patients in the study as compared with those without AKI (61.67% vs 27.43%, P<0.001) whereas spontaneous resolution of AKI was seen in 25 patients (41.67%, P<0.001). Only 4 patients (6.67%, P=0.001) who had renal replacement therapy had worsening renal function compared to the 27 patients (45%, P<0.001) who did not receive renal replacement therapy.
Conclusion Risk factors for MI-AKI include moderate to severe NIHSS score, chronic kidney disease 3 and above, cardiovascular disease, and high-dose mannitol infusion. Early nephrology referral among patients with mannitol infusion for stroke is a must among patients who have co-morbidities including chronic kidney disease stage 3 and above, and cardiovascular disease such as heart failure. Serial monitoring of renal function should be performed especially for those patients with moderate to severe NIHSS scores and high-dose mannitol infusion for appropriate dosing to prevent MI-AKI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institution and Ethics Review Board of EAMC reviewed and approved the protocol and all relevant documents before data collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Sources of funding This study was self-funded by the authors.
Data Availability
Data cannot be shared publicly because of Data Privacy Act of 2012 and the National Guidelines for Health and Health-Related Research (2007). Data are available from the Medical Records of EAMC for researchers who meet the criteria for access to confidential data.